{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:43:50Z","timestamp":1792514630309,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.yjmcc.2024.11.014","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T19:40:06Z","timestamp":1733168406000},"page":"99-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The sodium\/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner"],"prefix":"10.1016","volume":"198","author":[{"given":"Lynn C.","family":"Lunsonga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Fatehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentong","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkapravo","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Light","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.yjmcc.2024.11.014_bb0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejheart.2006.08.007","article-title":"Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability","volume":"9","author":"Maltsev","year":"2007","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.yjmcc.2024.11.014_bb0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/jmcc.1996.0254","article-title":"The role of the Na+ channel in the accumulation of intracellular Na+ during myocardial ischemia: consequences for post-ischemic recovery","volume":"29","author":"van Emous","year":"1997","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2024.11.014_bb0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/cvr\/cvr252","article-title":"Biology of cardiac sodium channel Nav1.5 expression","volume":"93","author":"Rook","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.yjmcc.2024.11.014_bb0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-642-41588-3_7","article-title":"The role of late I Na in development of cardiac arrhythmias","volume":"221","author":"Antzelevitch","year":"2014","journal-title":"Handb. Exp. Pharmacol."},{"issue":"7","key":"10.1016\/j.yjmcc.2024.11.014_bb0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/CIRCULATIONAHA.115.017980","article-title":"Late INa in the heart","volume":"132","author":"Makielski","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.yjmcc.2024.11.014_bb0030","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/pr.110.003723","article-title":"Drug-induced long QT syndrome","volume":"62","author":"Kannankeril","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.yjmcc.2024.11.014_bb0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1172-3-18","article-title":"Congenital long QT syndrome","volume":"3","author":"Crotti","year":"2008","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.yjmcc.2024.11.014_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030692","article-title":"Ion Channel disorders and sudden cardiac death","volume":"19","author":"Garcia-Elias","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2024.11.014_bb0045","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fphar.2020.01182","article-title":"Gating properties of mutant sodium channels and responses to sodium current inhibitors predict Mexiletine-sensitive mutations of Long QT syndrome 3","volume":"11","author":"Li","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.yjmcc.2024.11.014_bb0050","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ejhg.2012.23","article-title":"High prevalence of genetic variants previously associated with LQT syndrome in new exome data","volume":"20","author":"Refsgaard","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.yjmcc.2024.11.014_bb0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ipej.2017.10.011","article-title":"The congenital long QT syndrome type 3: an update","volume":"18","author":"P\u00e9rez-Riera","year":"2018","journal-title":"Ind. Pac. Electrophysiol. J."},{"issue":"12","key":"10.1016\/j.yjmcc.2024.11.014_bb0060","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCULATIONAHA.116.021823","article-title":"Clinical aspects of type 3 Long-QT syndrome","volume":"134","author":"Wilde","year":"2016","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.yjmcc.2024.11.014_bb0065","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.110.950147","article-title":"Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT syndrome implantable cardioverter-defibrillator (LQTS ICD) registry","volume":"122","author":"Schwartz","year":"2010","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.yjmcc.2024.11.014_bb0070","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.yjmcc.2024.11.014_bb0075","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the Spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.yjmcc.2024.11.014_bb0080","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.yjmcc.2024.11.014_bb0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.yjmcc.2024.11.014_bb0090","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with Empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.yjmcc.2024.11.014_bb0095","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.yjmcc.2024.11.014_bb0100","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"36","key":"10.1016\/j.yjmcc.2024.11.014_bb0105","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1093\/eurheartj\/ehab563","article-title":"Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure","volume":"42","author":"Light","year":"2021","journal-title":"Eur. Heart J."},{"issue":"36","key":"10.1016\/j.yjmcc.2024.11.014_bb0110","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1093\/eurheartj\/ehab560","article-title":"Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF","volume":"42","author":"Curtain","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.yjmcc.2024.11.014_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.810791","article-title":"Sodium-glucose cotransporter 2 inhibitors and heart failure: a bedside-to-bench journey","volume":"8","author":"Cappetta","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"4","key":"10.1016\/j.yjmcc.2024.11.014_bb0120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"issue":"1","key":"10.1016\/j.yjmcc.2024.11.014_bb0125","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) Inflammasome activation in heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ. Heart Fail."},{"issue":"4","key":"10.1016\/j.yjmcc.2024.11.014_bb0130","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail."},{"issue":"22","key":"10.1016\/j.yjmcc.2024.11.014_bb0135","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac late Sodium Channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor Empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.yjmcc.2024.11.014_bb0140","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.bjp.0706897","article-title":"Inhibition of cardiac voltage-gated sodium channels by grape polyphenols","volume":"149","author":"Wallace","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.yjmcc.2024.11.014_bb0145","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/hc1002.105183","article-title":"Na+ channel mutation that causes both Brugada and Long-QT syndrome phenotypes","volume":"105","author":"Clancy","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2024.11.014_bb0150","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48890","article-title":"Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block","volume":"8","author":"Tomek","year":"2019","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.yjmcc.2024.11.014_bb0155","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1469-7793.1998.647bp.x","article-title":"Structure and function of voltage-gated sodium channels","volume":"508","author":"Marban","year":"1998","journal-title":"J. Physiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2024.11.014_bb0160","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1152\/physrev.00024.2004","article-title":"Sodium Channel inactivation: molecular determinants and modulation","volume":"85","author":"Ulbricht","year":"2005","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.yjmcc.2024.11.014_bb0165","doi-asserted-by":"crossref","first-page":"C577","DOI":"10.1152\/ajpcell.00125.2011","article-title":"Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice","volume":"301","author":"Yao","year":"2011","journal-title":"Am. J. Phys. Cell Physiol."},{"issue":"3","key":"10.1016\/j.yjmcc.2024.11.014_bb0170","doi-asserted-by":"crossref","first-page":"C557","DOI":"10.1152\/ajpcell.00189.2011","article-title":"A molecular formula for heart failure and sudden cardiac death. Focus on \u201cNav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice\u201d","volume":"301","author":"Kaczorowski","year":"2011","journal-title":"Am. J. Phys. Cell Physiol."},{"issue":"2","key":"10.1016\/j.yjmcc.2024.11.014_bb0175","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bbrc.2006.11.019","article-title":"Characterization of the cardiac sodium channel SCN5A mutation, N1325S, in single murine ventricular myocytes","volume":"352","author":"Yong","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.yjmcc.2024.11.014_bb0180","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijcard.2009.08.047","article-title":"LQTS mutation N1325S in cardiac sodium channel gene SCN5A causes cardiomyocyte apoptosis, cardiac fibrosis and contractile dysfunction in mice","volume":"147","author":"Zhang","year":"2011","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.yjmcc.2024.11.014_bb0185","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cardiores.2003.11.007","article-title":"Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo","volume":"61","author":"Tian","year":"2004","journal-title":"Cardiovasc. Res."},{"issue":"9","key":"10.1016\/j.yjmcc.2024.11.014_bb0190","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/hmg\/4.9.1603","article-title":"Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia","volume":"4","author":"Wang","year":"1995","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.yjmcc.2024.11.014_bb0195","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.bbrc.2006.11.106","article-title":"Optical mapping of ventricular arrhythmias in LQTS mice with SCN5A mutation N1325S","volume":"352","author":"Tian","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.yjmcc.2024.11.014_bb0200","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1161\/CIRCULATIONAHA.106.646513","article-title":"Cardiac sodium channel dysfunction in sudden infant death syndrome","volume":"115","author":"Wang","year":"2007","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.yjmcc.2024.11.014_bb0205","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1113\/jphysiol.2012.235374","article-title":"The human Nav1.5 F1486 deletion associated with long QT syndrome leads to impaired sodium channel inactivation and reduced lidocaine sensitivity","volume":"590","author":"Song","year":"2012","journal-title":"J. Physiol."},{"issue":"8","key":"10.1016\/j.yjmcc.2024.11.014_bb0210","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1172\/JCI0215570","article-title":"Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation","volume":"110","author":"Grant","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.yjmcc.2024.11.014_bb0215","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.yjmcc.2003.08.007","article-title":"A novel mutation in SCN5A, delQKP 1507-1509, causing long QT syndrome: role of Q1507 residue in sodium channel inactivation","volume":"35","author":"Keller","year":"2003","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2024.11.014_bb0220","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.recesp.2018.03.009","article-title":"Digenic Heterozigosity in SCN5A and CACNA1C explains the variable expressivity of the Long QT phenotype in a Spanish family","volume":"72","author":"Nieto-Mar\u00edn","year":"2019","journal-title":"Rev. Esp. Cardiol."},{"issue":"2","key":"10.1016\/j.yjmcc.2024.11.014_bb0225","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00395-016-0530-0","article-title":"Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction","volume":"111","author":"Malan","year":"2016","journal-title":"Basic Res. Cardiol."},{"issue":"11","key":"10.1016\/j.yjmcc.2024.11.014_bb0230","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/jmedgenet-2017-104780","article-title":"Novel idiopathic DCM-related SCN5A variants localised in DI-S4 predispose electrical disorders by reducing peak sodium current density","volume":"54","author":"Shen","year":"2017","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.yjmcc.2024.11.014_bb0235","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1085\/jgp.201210899","article-title":"Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics","volume":"141","author":"Terrenoire","year":"2013","journal-title":"J. Gen. Physiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2024.11.014_bb0240","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1161\/CIRCGENETICS.114.000831","article-title":"Enhanced classification of Brugada syndrome-associated and Long-QT syndrome-associated genetic variants in the SCN5A-encoded Na(v)1.5 cardiac Sodium Channel","volume":"8","author":"Kapplinger","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.yjmcc.2024.11.014_bb0245","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2147\/DDDT.S133944","article-title":"Modeling the human Na(v)1.5 sodium channel: structural and mechanistic insights of ion permeation and drug blockade","volume":"11","author":"Ahmed","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.yjmcc.2024.11.014_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.842645","article-title":"Fenestropathy of voltage-gated sodium channels","volume":"13","author":"Gamal El-Din","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.yjmcc.2024.11.014_bb0255","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0014-5793(00)01875-5","article-title":"A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome","volume":"479","author":"Akai","year":"2000","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.yjmcc.2024.11.014_bb0260","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0008-6363(02)00838-6","article-title":"A novel LQT3 mutation implicates the human cardiac sodium channel domain IVS6 in inactivation kinetics","volume":"57","author":"Groenewegen","year":"2003","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.yjmcc.2024.11.014_bb0265","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tcm.2015.05.006","article-title":"Late sodium current: a mechanism for angina, heart failure, and arrhythmia","volume":"26","author":"Makielski","year":"2016","journal-title":"Trends Cardiovasc. Med."},{"issue":"5","key":"10.1016\/j.yjmcc.2024.11.014_bb0270","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1085\/jgp.20028679","article-title":"Tracking voltage-dependent conformational changes in skeletal muscle sodium channel during activation","volume":"120","author":"Chanda","year":"2002","journal-title":"J. Gen. Physiol."},{"issue":"8","key":"10.1016\/j.yjmcc.2024.11.014_bb0275","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1073\/pnas.1817446116","article-title":"Structural basis for antiarrhythmic drug interactions with the human cardiac sodium channel","volume":"116","author":"Nguyen","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6744","key":"10.1016\/j.yjmcc.2024.11.014_bb0280","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/23034","article-title":"Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia","volume":"400","author":"Clancy","year":"1999","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.yjmcc.2024.11.014_bb0285","article-title":"Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation","volume":"7","author":"O\u2019Hara","year":"2011","journal-title":"PLoS Comput. Biol."},{"issue":"12","key":"10.1016\/j.yjmcc.2024.11.014_bb0290","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.hrthm.2010.09.017","article-title":"Early afterdepolarizations and cardiac arrhythmias","volume":"7","author":"Weiss","year":"2010","journal-title":"Heart Rhythm."},{"issue":"12","key":"10.1016\/j.yjmcc.2024.11.014_bb0295","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/imj.15437","article-title":"Congenital long QT syndrome: a clinician\u2019s guide","volume":"51","author":"Lankaputhra","year":"2021","journal-title":"Intern. Med. J."},{"issue":"4","key":"10.1016\/j.yjmcc.2024.11.014_bb0300","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/CIRCRESAHA.118.314050","article-title":"Predicting patient response to the antiarrhythmic Mexiletine based on genetic variation","volume":"124","author":"Zhu","year":"2019","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.yjmcc.2024.11.014_bb0305","first-page":"H179","article-title":"Modeling incomplete penetrance in long QT syndrome type 3 through ion channel heterogeneity: an in silico population study","volume":"324","author":"Miller","year":"2023","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"issue":"23","key":"10.1016\/j.yjmcc.2024.11.014_bb0310","doi-asserted-by":"crossref","first-page":"13200","DOI":"10.1073\/pnas.93.23.13200","article-title":"Characterization of human cardiac Na+ channel mutations in the congenital long QT syndrome","volume":"93","author":"Wang","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"Suppl. 4","key":"10.1016\/j.yjmcc.2024.11.014_bb0315","first-page":"iv1","article-title":"Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload","volume":"92","author":"Noble","year":"2006","journal-title":"Heart"},{"issue":"23","key":"10.1016\/j.yjmcc.2024.11.014_bb0320","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/01.CIR.98.23.2545","article-title":"Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes","volume":"98","author":"Maltsev","year":"1998","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.yjmcc.2024.11.014_bb0325","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1161\/CIRCULATIONAHA.122.057364","article-title":"Empagliflozin inhibits cardiac late sodium current by ca\/calmodulin-dependent kinase II","volume":"146","author":"Mustroph","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.yjmcc.2024.11.014_bb0330","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus","volume":"4","author":"Heise","year":"2013","journal-title":"Diabetes Ther."},{"issue":"3","key":"10.1016\/j.yjmcc.2024.11.014_bb0335","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin. Pharmacokinet."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282824002049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282824002049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T12:49:59Z","timestamp":1741178999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282824002049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":67,"alternative-id":["S0022282824002049"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2024.11.014","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.15.589662","asserted-by":"object"}]},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The sodium\/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2024.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}